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Stem cell therapy is a promising approach to cure degen-
erative diseases, cancer, damaged tissues, or any disease for
which there are very limited therapeutic options. Stem cell
therapies could potentially improve the efficiency of the
human body regenerative response following an injury or
insult, in addition to being a source of powerful therapeutic
compounds that hold the promise of the restoration of
normal function of a given tissue. The abilities to identify,
isolate, expand, and differentiate stem cells have been past
barriers for developing therapies in patients and treatments
using stem cells have long been viewed as potential or under
development.The discovery of induced pluripotent stem cells
(iPSC) has encouraged many researchers in the field of stem
cell biology and organized-patient groups to advocate for
increased development of stem cell-based therapies and in-
depth scientific knowledge.
The field of regenerative medicine and the ability to har-
ness and manipulate stem cells to treat human diseases have
been opened by a combination of many technical advances
[1]. A few, among these improved technologies, should
be mentioned. Whole transcriptome analyses have allowed
researchers to better understand the molecular signatures of
different stem cell populations in human tissues and rodent
models [2]. New methods in generating novel transgenic
models have allowed researchers to perform elegant lineage
tracing of stem cells as they proliferate and differentiate into
specific somatic lineages [3–5]. Improvements in techniques
to prospectively isolate stem cell populations, manipulate
their genomes, and image/track them have also greatly
improved in the past decade [6–8]. Advances in large scale
genetic and drug library screening have also allowed an
unprecedented insight into themolecular changes and factors
necessary to convert pluripotent cells into progenitors of
specific lineages [9].
Last year, clinical trials using retinal pigment epithelium
derived from iPS cells were performed for patients who
had severe age-related macular degradation in Japan [10,
11]. These trials evaluated the safety of iPS cells generated
from the recipient’s own cells and they have shown that the
iPS cells did not evoke any immune reactions and did not
produce tumors in mice and monkeys before conducting
transplants. So far, no problems or health concerns have been
reported, suggesting that iPS cells constitute an additional
option for stem cell-based therapies. One remaining concern
is whether the engrafted iPS cells will be working as part of
the regenerating tissue and whether the transplanted cells
will persist for a long time. Another exciting report this
year was a US-based clinical trial from Robert Lanza’s group
at Advanced Cell Technology, demonstrating efficacy and
tolerance of human embryonic stem (ES) cell-derived retinal
pigment epithelium cells transplanted into patients with
Stargardt’smacular dystrophy [12].This phase 1/2 clinical trial
did not show any adverse effects and an improvement in
visual function in a significant number of patients receiving
the transplanted cells was observed.These findings have given
patients with previously untreatable degenerative disorders
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hope for a potential regenerative stem-cell based treatment.
The current state of development of stem cell-based therapies
for different conditions is reviewed by J. F. Stoltz et al. and
R. Compagna et al., in this issue. Additional potential for
therapies may lie in the ability to harness the power of
mesenchymal stem cells (MSCs). Mesenchymal stem cells are
stem cells that developmentally originate from the embryonic
mesoderm and are thought to be involved in the regeneration
and tissue repair processes of several organs including the
bone, vasculature, connective ligaments, and liver [13, 14].
It is this therapeutic potential of MSCs that makes them
attractive for potential clinical therapies, as evident by studies
of bone-marrow and tendon-derivedmesenchymal stem cells
of regenerative potential by M. K. Al-ani et al. in this issue.
Additional work on the differentiation potential of various
MSCs (such as that by D. J. Zhang et al. in this issue) into
more somatic lineages highlights the progress made towards
directed lineage conversion of specific stem cell populations.
Despite these promising initial studies, potential and
unanticipated risks and complications or side effects might
become apparent with progress of stem cell-based therapies.
Continued research is fundamental for the evaluation and
exclusion of potential risks before the clinical use of stem
cells. It is difficult, however, to predict with certainty the risk
of these therapies due to the number and complexity of the
variables involved, such as type of stem or progenitor cells,
their proliferation or differentiation capacity, themethods for
their isolation and route of administration, the engraftment
location, and others derived from the recipients’ age or health
condition. Rigorous preclinical experiments and safety trials
are needed to address some of these issues whose designmust
take into account both observations from clinical experience
and from animal studies including tumor formation and/or
immune responses. Understanding the basic biology and
differentiation potential of stem cells (as in the study of the
SDF-1/CXCR4 axis as a regulator of MSCs to repair liver
injury by N.-B. Hao et al. in this issue) might be an important
clue to solve some of these downstream problems. It is well
known that stem cells not only work as a part of tissue
regeneration, but also secrete factors for maintenance and
well-being of tissue homeostasis, for example, by promot-
ing vasculature, suppressing inflammation, or accelerating
cell growth. Interesting examples of these mechanisms are
described in the studies by A. L. Strong et al. and D. J. Zhang
et al. included in this issue.
A remaining significant hurdle for scientists and clini-
cians is the growing number of unregulated stem cell clinics
[15]. False promises of miracle cures using stem cells have
led to the burgeoning industry of stem cell tourism, where
patients travel outside of countries with strong regulation of
stem cell uses to countries where stem cell regulations are
more lax [16]. As we move forward in advancing rational
therapies for treating patients, it is important for the field to
ensure patient safety and openness of sharing all clinical trial
results, both positive and negative, with the public.
In this special issue, we present a collection of studies
and reviews that highlight a broad variety of topics related
to stem cell differentiation and potential therapeutic use. We
hope that the readers will appreciate the amount of progress
in addition to the challenges that have been made in the
past decade towards understanding and characterizing stem
cells from embryonic to adult stem cells. As is evident by
the investment made by several governmental and private
agencies, novel stem cell therapies are well on their way
to becoming a reality for patients dealing with debilitating
diseases.
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